Related Experiment Video
Updated: Mar 20, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia
G B Martinelli1, D Olivari1, A D Re Cecconi1
1Department of Oncology, IRCCS - Mario Negri Institute for Pharmacological Research, Milan, Italy.
Abstract:
Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.
Insights
Activating the CXCR4 pathway in muscle combats cancer cachexia by preventing muscle wasting. This involves regulating stromal cell-derived factor 1 (SDF1) and its receptor, offering a potential therapeutic target for this severe condition.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cancer cachexia is a severe, life-threatening syndrome causing significant muscle and body weight loss in advanced cancer patients.
- Currently, no effective treatments are available for cancer cachexia, highlighting an urgent need for therapeutic strategies.
Purpose of the Study:
- To identify specific molecular pathways altered in cancer cachexia.
- To investigate the role of the CXCR4 pathway in muscle wasting associated with cancer.
- To explore potential therapeutic targets for combating cancer cachexia.
Main Methods:
- Analysis of microarray data from cachectic rodent muscles and human tissues.
- Ingenuity Pathways Analysis to identify dysregulated genes and pathways.
- Gene expression correlation studies with ubiquitin ligases in cancer patient muscles.
- In vivo and in vitro experiments involving gene overexpression and pathway inhibition in muscle models.
Main Results:
- Downregulation of stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1) in cachectic muscles, linked to the CXCR4 pathway.
- Inverse correlation between SDF1/CXCR4 expression and muscle-wasting ubiquitin ligases (atrogin-1, MuRF1) in cancer patients.
- Overexpressing SDF1 or CXCR4 increased muscle fiber area by 20% and protected against wasting.
- SDF1 treatment reduced protein degradation in atrophying myotubes, while CXCR4 inhibition affected normal myotubes, confirming pathway involvement.
Conclusions:
- The CXCR4 pathway, specifically involving SDF1, plays a critical role in suppressing cancer-induced muscle wasting.
- Activating the CXCR4 pathway in muscle represents a promising therapeutic strategy to counteract cancer cachexia.
- Findings suggest targeting the SDF1-CXCR4 axis could offer a novel treatment for cancer cachexia.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Cross-bridge Cycle
Anaphase Promoting Complex
Satellite Stem Cells and Muscular Dystrophy

